December 16, 2024 06:45 AM EST

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Ayisha Sharma

News Reporter

Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark

FTC OKs Novo-Catalent deal in major win for Novo Nordisk’s GLP-1 manufacturing

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

No­vo Nordisk to spend $1.2B for new rare dis­ease drug fac­to­ry in Den­mark

FTC OKs No­vo-Catal­ent deal in ma­jor win for No­vo Nordisk’s GLP-1 man­u­fac­tur­ing

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark

FTC OKs Novo-Catalent deal in major win for Novo Nordisk’s GLP-1 manufacturing